Examining the impact of changes to diagnostic criteria on Autism Spectrum and Attention Deficit Hyperactivity Disorders

点击翻译按钮获取中文摘要

Genome-wide association (GWAS) has recently identified the first common variants influencing Autism Spectrum and Attention Deficit Hyperactivity Disorders (ASD and ADHD) demonstrating that increasing power is key to identifying new treatment targets and biomarkers. We seek to assess how changes to the criteria used to diagnose ASD and ADHD affect the symptom profile, cost of treatment and generalisation of GWAS results, to determine the implications of these changes for personalised medicine.